Morgan Stanley analyst Terence Flynn raised the firm’s price target on Regeneron (REGN) to $768 from $767 and keeps an Equal Weight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target raised to $985 from $890 at HSBC
- Kymera Therapeutics price target raised to $120 from $67 at Oppenheimer
- Regeneron announces data from Phase 1/2 LINKER-MM4 trial
- Regeneron price target raised to $850 from $725 at BMO Capital
- Regeneron price target raised to $1,057 from $850 at Canaccord